These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 19006114

  • 1. Safety of spironolactone use in ambulatory heart failure patients.
    Lopes RJ, Lourenço AP, Mascarenhas J, Azevedo A, Bettencourt P.
    Clin Cardiol; 2008 Nov; 31(11):509-13. PubMed ID: 19006114
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?
    Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D.
    J Card Fail; 2004 Aug; 10(4):297-303. PubMed ID: 15309695
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Safety of spironolactone use in ambulatory heart failure patients.
    Kandula P, Shah R.
    Clin Cardiol; 2009 Jun; 32(6):347-8. PubMed ID: 19569078
    [No Abstract] [Full Text] [Related]

  • 8. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease.
    Pitt B, Bushinsky DA, Kitzman DW, Ruschitzka F, Metra M, Filippatos G, Rossignol P, Du Mond C, Garza D, Berman L, Lainscak M, Patiromer-204 Investigators.
    ESC Heart Fail; 2018 Jun; 5(3):257-266. PubMed ID: 29369537
    [Abstract] [Full Text] [Related]

  • 9. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure.
    Shah KB, Rao K, Sawyer R, Gottlieb SS.
    J Am Coll Cardiol; 2005 Sep 06; 46(5):845-9. PubMed ID: 16139135
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B, EMPHASIS-HF Investigators.
    J Am Coll Cardiol; 2013 Oct 22; 62(17):1585-93. PubMed ID: 23810881
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Frequency and predictors of hyperkalemia in patients ≥60 years of age with heart failure undergoing intense medical therapy.
    Muzzarelli S, Maeder MT, Toggweiler S, Rickli H, Nietlispach F, Julius B, Burkard T, Pfisterer ME, Brunner-La Rocca HP, TIME-CHF Investigators.
    Am J Cardiol; 2012 Mar 01; 109(5):693-8. PubMed ID: 22152974
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES).
    Pitt D.
    Eur Heart J; 1995 Dec 01; 16 Suppl N():107-10. PubMed ID: 8682055
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients.
    Hammer F, Malzahn U, Donhauser J, Betz C, Schneider MP, Grupp C, Pollak N, Störk S, Wanner C, Krane V, MiREnDa Study Group.
    Kidney Int; 2019 Apr 01; 95(4):983-991. PubMed ID: 30712923
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.